Australian Clinical Labs First Take Soft Result

Australian Clinical Labs (ACL) delivered a weak 1H26 result with revenue missing estimates and a subsequent downgrade to FY26 guidance.

Key Takeaways

• 1.ACL reported a soft 1H26 result with total revenue missing estimates by approximately 3-4%.
• 2.The company downgraded its FY26 guidance for revenue and EBIT by roughly 4% and 6% respectively at the mid-point.
• 3.Results include a $1.8m impact from gender undervaluation and exclude $1.4m in historical employee underpayments.

Table of Contents

• Key 1H26 result highlights
• FY26 outlook
• Price Target Risks and Methodology - Australian Clinical Labs
• Investment Thesis - Australian Clinical Labs
• Disclosure Appendix
• GS Factor Profile
• M&A Rank
• Quantum
• Disclosures
• Company-specific regulatory disclosures
• Distribution of ratings/investment banking relationships
• Price target and rating history chart(s)
• Regulatory disclosures

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial